Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating
1. Morgan Stanley predicts trial failure for Novo's weight-loss drug against Alzheimer's. 2. Price target lowered to $47 from $59, the most pessimistic on Wall Street. 3. Semaglutide has a 75% chance of failing to reduce dementia statistically. 4. Ozempic prescriptions are declining, while Lilly's Mounjaro prescriptions grow. 5. Medicare Part D may cut semaglutide prices by 50%.